Tags

Type your tag names separated by a space and hit enter

Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Gynecol Oncol. 2009 Mar; 112(3):537-42.GO

Abstract

OBJECTIVE

The estrogen receptor (ER)-alpha and -beta and progesterone receptor (PR)-A and -B were determined in endometrioid endometrial cancer, and their prognostic values were assessed.

METHODS

Tissue microarrays were constructed from 315 endometrioid endometrial cancer patients. Receptor expression was assessed by immunostaining, and their semi-quantitatively determined expression levels were correlated to classical clinico-histopathological parameters in addition to disease free and disease specific survival.

RESULTS

Patients were classified as FIGO stage I (59.0%), stage II (17.1%), stage III (19.4%) and stage IV (4.1%). Sixty-five patients (20.6%) developed recurrent disease and 38 (12.1%) died due to endometrial cancer. In univariate analysis, expression of ER-alpha was related to early stage endometrial cancer (p=0.020), while expression of ER-alpha, PR-A and PR-B was associated with lower grade tumours (p<0.0001, p<0.001 and p=0.001 respectively). A ratio of ER-alpha/ER-beta <1 was related to a shorter disease free survival (p=0.027), while the ratio of PR-A/PR-B <1 both was associated with a shorter disease free survival as well as a shorter overall survival (p=0.044 and p=0.005, respectively). In early stage disease, using multivariate analysis, absence of ER-alpha was independently related to death of disease (p=0.017, OR 7.28, 95% CI 1.42-37.25), while absence of PR-A (p=0.015, OR 4.2, 95% CI 1.32-13.33) appeared to be an independent prognostic factor for relapse of disease.

CONCLUSION

We conclude that in early stage endometrioid endometrial cancer absence of PR-A is an independent prognostic factor for disease-free survival, while patients with ER-alpha positive tumours have a better overall survival.

Authors+Show Affiliations

Department of Gynaecologic Oncology, University Medical Center Groningen, University of Groningen, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19108875

Citation

Jongen, Vincent, et al. "Expression of Estrogen Receptor-alpha and -beta and Progesterone receptor-A and -B in a Large Cohort of Patients With Endometrioid Endometrial Cancer." Gynecologic Oncology, vol. 112, no. 3, 2009, pp. 537-42.
Jongen V, Briët J, de Jong R, et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol. 2009;112(3):537-42.
Jongen, V., Briët, J., de Jong, R., ten Hoor, K., Boezen, M., van der Zee, A., Nijman, H., & Hollema, H. (2009). Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecologic Oncology, 112(3), 537-42. https://doi.org/10.1016/j.ygyno.2008.10.032
Jongen V, et al. Expression of Estrogen Receptor-alpha and -beta and Progesterone receptor-A and -B in a Large Cohort of Patients With Endometrioid Endometrial Cancer. Gynecol Oncol. 2009;112(3):537-42. PubMed PMID: 19108875.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. AU - Jongen,Vincent, AU - Briët,Justine, AU - de Jong,Renske, AU - ten Hoor,Klaske, AU - Boezen,Marike, AU - van der Zee,Ate, AU - Nijman,Hans, AU - Hollema,Harry, Y1 - 2008/12/23/ PY - 2008/05/23/received PY - 2008/10/17/revised PY - 2008/10/31/accepted PY - 2008/12/26/entrez PY - 2008/12/26/pubmed PY - 2009/3/17/medline SP - 537 EP - 42 JF - Gynecologic oncology JO - Gynecol Oncol VL - 112 IS - 3 N2 - OBJECTIVE: The estrogen receptor (ER)-alpha and -beta and progesterone receptor (PR)-A and -B were determined in endometrioid endometrial cancer, and their prognostic values were assessed. METHODS: Tissue microarrays were constructed from 315 endometrioid endometrial cancer patients. Receptor expression was assessed by immunostaining, and their semi-quantitatively determined expression levels were correlated to classical clinico-histopathological parameters in addition to disease free and disease specific survival. RESULTS: Patients were classified as FIGO stage I (59.0%), stage II (17.1%), stage III (19.4%) and stage IV (4.1%). Sixty-five patients (20.6%) developed recurrent disease and 38 (12.1%) died due to endometrial cancer. In univariate analysis, expression of ER-alpha was related to early stage endometrial cancer (p=0.020), while expression of ER-alpha, PR-A and PR-B was associated with lower grade tumours (p<0.0001, p<0.001 and p=0.001 respectively). A ratio of ER-alpha/ER-beta <1 was related to a shorter disease free survival (p=0.027), while the ratio of PR-A/PR-B <1 both was associated with a shorter disease free survival as well as a shorter overall survival (p=0.044 and p=0.005, respectively). In early stage disease, using multivariate analysis, absence of ER-alpha was independently related to death of disease (p=0.017, OR 7.28, 95% CI 1.42-37.25), while absence of PR-A (p=0.015, OR 4.2, 95% CI 1.32-13.33) appeared to be an independent prognostic factor for relapse of disease. CONCLUSION: We conclude that in early stage endometrioid endometrial cancer absence of PR-A is an independent prognostic factor for disease-free survival, while patients with ER-alpha positive tumours have a better overall survival. SN - 1095-6859 UR - https://www.unboundmedicine.com/medline/citation/19108875/Expression_of_estrogen_receptor_alpha_and__beta_and_progesterone_receptor_A_and__B_in_a_large_cohort_of_patients_with_endometrioid_endometrial_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-8258(08)00934-7 DB - PRIME DP - Unbound Medicine ER -